XORTX Therapeutics Inc.
XRTX.V
TSX
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -521.93% | 76.86% | -95.46% | 55.98% | 110.05% |
| Total Depreciation and Amortization | -16.36% | -19.00% | 6.97% | 56.97% | 3.13% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 89.41% | -111.84% | 78.86% | -1,131.25% | -6,202.29% |
| Change in Net Operating Assets | -90.02% | 181.65% | 33.96% | -74.48% | 790.26% |
| Cash from Operations | -7.74% | 50.63% | 31.72% | 29.77% | 57.41% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -139.56% | -30.77% | 59.18% | -217.81% | -15.19% |
| Cash from Investing | -139.56% | -30.77% | 59.18% | -217.81% | 4.21% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -161.80% | -45.28% | -33.53% | -32.93% | 45.73% |
| Issuance of Common Stock | -- | -94.37% | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 92.34% | -25.40% | -- | -100.00% |
| Cash from Financing | -387.64% | -96.03% | 454.47% | -32.93% | 11.88% |
| Foreign Exchange rate Adjustments | 1,180.00% | 111.83% | -2,813.33% | 9,850.00% | -154.35% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -9.88% | -249.15% | 110.66% | 28.97% | 56.60% |